Iovance Biotherapeutics, Inc. Common Stock
Symbol: IOVA (NASDAQ)
1.81
▲ (9.04%) 0.150
Company Description:
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Key Stats
- Today's Open: $1.64
- Today's High: $1.84
- Today's Low: $1.536
- Today's Volume: 15.21M
- Yesterday Close: $1.66
- Yesterday High: $1.72
- Yesterday Low: $1.64
- Yesterday Volume: 19.52M
- Last Min Volume: 2.31K
- Last Min High: $1.81
- Last Min Low: $1.81
- Last Min VWAP: $1.81
Company Profile
- Name: Iovance Biotherapeutics, Inc. Common Stock
- Website: https://www.iovance.com
- Listed Date: 2010-10-15
- Location: SAN CARLOS, CA
- Market Status: Active
- CIK Number: 0001425205
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $644.49M
- Round Lot: 100
- Outstanding Shares: 333.93M
- Asset Type: CS
RECENT FILINGS FOR IOVA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-05-16 | 4 | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-04-30 | ARS | View |
| 2025-04-28 | DEFA14A | View |
| 2025-04-28 | DEF 14A | View |
| 2025-03-18 | 4 | View |
| 2025-03-07 | 4 | View |
| 2025-03-07 | 4 | View |
| 2025-03-07 | 4 | View |
| 2025-03-07 | 4 | View |
| 2025-03-07 | 4 | View |
| 2025-03-05 | 4 | View |
| 2025-03-05 | 4 | View |
| 2025-03-05 | 4 | View |
| 2025-03-05 | 4 | View |
| 2025-03-05 | 4 | View |
| 2025-02-27 | 10-K | View |
| 2025-02-27 | 8-K | View |
Latest News on IOVA